Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Emerging
Primary summary from verified readiness
- Confidence
- 73% · stale
- Computed at
- 2026-09-30T20:06:03.145208+00:00
- Claimed
- 65
- Reported
- 41
- Verified
- 28
- Gap
- +37
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Agent-assisted assessment · independently reviewed · 2026-09-30
Elevidys warrants specialist consideration only within its current approved indication and safety requirements.
- Why
- Clinical deployment and encouraging longer-term comparisons coexist with uncertain randomized functional benefit and potentially fatal liver injury.
- Next
- Use the current local prescribing information and specialist benefit-risk assessment, including eligibility, monitoring capacity and alternative care options.
Constraints
Blockers
- Potentially fatal liver injury requires intensive monitoring and specialist access.
- The randomized trial failed its primary motor-function endpoint.
- Longer-term efficacy comparisons use external controls.
- Eligibility is restricted by ambulatory status, age, mutation and antibody screening.
- Durable benefit and the full postmarketing safety profile remain uncertain.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 10
- Tier 1
- 5
- Tier 2
- 5
- Tier 3
- 0
- Supports
- 2
- Contradicts
- 6
- Context
- 2
- Latest observed
- 2026-01-26
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Revision 3
- 2026-08-20 Reading moved from emerging to emerging.
- 2026-09-22 Reading moved from emerging to emerging.
- 2026-09-30 Reading moved from emerging to emerging.